GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.
Using PRP or Exosome treatments alongside Finasteride/Dutasteride and Minoxidil may not significantly enhance results. Dutasteride and oral Minoxidil are considered more effective options.
A user solved their 15-year scalp inflammation and related hair loss using Selenium Sulfide shampoo (Selsun Blue), noticing improvement after the first use and resolution after three uses. Others found relief with Ketoconazole shampoo, which also helps with hair loss.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.
RU58841 is being considered for hair maintenance by someone who can't tolerate finasteride. Alternatives like topical finasteride, dutasteride, and KX826 are also suggested.
The conversation discusses the lack of promising results from the 23rd Annual Meeting of Japan Society of Clinical Hair Restoration, with no significant advancements expected in the next five years. Treatments mentioned include setipiprant, with skepticism about its effectiveness.
The conversation discusses the potential effectiveness and risks of using topical finasteride for hair loss, with considerations about using DMSO as a vehicle for application. Concerns are raised about DMSO's safety, absorption issues, and the systemic effects of topical finasteride.
The conversation discusses the effectiveness and authenticity of RU58841 purchased from Amazon, with some users suggesting buying from reputable sources like Anagen Inc. Others recommend using oral finasteride instead of RU58841 due to concerns about product legitimacy.
The conversation is about Kintor's announcement indicating continued hope for their product KX-826 as a treatment for Alopecia Androgenetica. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.
The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.
The conversation is about making a solution of RU58841 using propanediol instead of propylene glycol due to skin irritation. The user seeks advice on whether this substitution is acceptable.
The user mixes their own RU58841 solution and found that increasing the ethanol content improved absorption and reduced scalp itching. A study on minoxidil showed that penetration increased with higher ethanol concentrations, reaching maximum penetration at 90% ethanol.
PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.
The user is considering adding RU58841 to their current hair loss treatment of finasteride and minoxidil, but is concerned about potential side effects like hairline recession and shedding. Some users report positive results with RU58841, while others experience side effects such as chest pain and dizziness.
The user has been using a topical solution containing minoxidil and finasteride for 10 months but is not satisfied with the results, as there is no significant hair regrowth or thickening. They are questioning whether they are a non-responder or if they should continue the treatment longer.
Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.
Exploring potential treatments for hair loss, such as Minoxidil, Finasteride, RU58841 and Pyrilutamide. The user is looking for feedback on whether KX-826 can be used successfully as a single therapy to stop the miniaturization process.
A user discusses the legitimacy of Kintor's KX-826 for hair loss, available on Amazon through Koshine Biomedica. They decided to order it after finding a document linking Kintor and Koshine as collaborators.
PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.
A user shared their 2-year progress using finasteride every other day with no side effects. Others discussed their experiences, shedding cycles, and patience with the treatment.
PP405 is a potential hair loss treatment showing promising early results, with hopes for market release by 2028, but skepticism remains due to inconclusive data and past disappointments with similar products. Current treatments like Minoxidil and Finasteride have side effects, leading some to anticipate PP405 as a safer alternative, though its effectiveness compared to placebo is debated.
The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references upcoming trial data from Shiseido in Japan.
The user is using oral finasteride, minoxidil, and KX-826 for hair regrowth, noticing small improvements. They plan to add ketoconazole shampoo and consider a hair transplant with verteporfin after a year of treatment.
The conversation is about concerns over the authenticity of oral minoxidil for hair loss treatment, with fears it might contain finasteride despite labeling. Users reassure that if it states minoxidil only, it should be trusted, and mention that Indian drugs are generally okay.
A 51-year-old on TRT plans to use steroids and is concerned about hair loss, considering topical treatments like Hair Rescue with RU58841 and finasteride, along with Nioxin shampoo. They are cautious about using oral DHT blockers due to potential interactions with steroids like Tren and Anavar.
User is experiencing issues with Minoxidil and is considering switching to Redensyl, specifically asking for brand recommendations. The Ordinary - Multi Peptide is mentioned, but the user seeks other brand experiences.
User plans to switch from oral to .005% topical finasteride, using a solvent from minoxidilmax and later Essengen-F. They will monitor DHT levels and seek advice on solvents and sleep caps.
The user is using finasteride, RU58841, and various natural supplements and treatments like seamoss, fish oil, and black rice water spray to combat hair loss, avoiding minoxidil due to dependency concerns. They report thicker hair and regained confidence, while discussing the potential risks and benefits of RU58841 with others.